[go: up one dir, main page]

AU2001227717A1 - Enhancing lymph channel development and treatment of lymphatic obstructive disease - Google Patents

Enhancing lymph channel development and treatment of lymphatic obstructive disease

Info

Publication number
AU2001227717A1
AU2001227717A1 AU2001227717A AU2771701A AU2001227717A1 AU 2001227717 A1 AU2001227717 A1 AU 2001227717A1 AU 2001227717 A AU2001227717 A AU 2001227717A AU 2771701 A AU2771701 A AU 2771701A AU 2001227717 A1 AU2001227717 A1 AU 2001227717A1
Authority
AU
Australia
Prior art keywords
lymphatic
treatment
obstructive disease
channel development
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001227717A
Other languages
English (en)
Inventor
Stephen E Epstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001227717A1 publication Critical patent/AU2001227717A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001227717A 2000-01-11 2001-01-09 Enhancing lymph channel development and treatment of lymphatic obstructive disease Abandoned AU2001227717A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17539300P 2000-01-11 2000-01-11
US60175393 2000-01-11
PCT/US2001/000545 WO2001051075A1 (fr) 2000-01-11 2001-01-09 Amelioration du developpement des canaux lymphatiques, et traitement des maladies lymphatiques obstructives

Publications (1)

Publication Number Publication Date
AU2001227717A1 true AU2001227717A1 (en) 2001-07-24

Family

ID=22640063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001227717A Abandoned AU2001227717A1 (en) 2000-01-11 2001-01-09 Enhancing lymph channel development and treatment of lymphatic obstructive disease

Country Status (2)

Country Link
AU (1) AU2001227717A1 (fr)
WO (1) WO2001051075A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (fr) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)
CN116036106A (zh) * 2021-10-28 2023-05-02 上海中医药大学附属龙华医院 一种治疗淋巴水肿的药物运用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395928T1 (de) * 1997-12-24 2008-06-15 Ludwig Inst Cancer Res Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
WO2000058511A1 (fr) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)

Also Published As

Publication number Publication date
WO2001051075A1 (fr) 2001-07-19

Similar Documents

Publication Publication Date Title
IL158316A0 (en) Therapeutic and diagnostic uses of antibody specificity profiles
AUPR406501A0 (en) Treatment of vault prolapse
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AUPQ923100A0 (en) Treatment of prostate cancer
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2002231206A1 (en) Treatment of depression
AU2001296627A1 (en) Hemorrhoid treatment and prostate massage apparatus
AU2001227717A1 (en) Enhancing lymph channel development and treatment of lymphatic obstructive disease
AU2001245414A1 (en) Treatment of allergies
AU9402401A (en) Treatment of cancers
AU2002227272A1 (en) Ovarian tumor antigen and methods of use therefor
AU2001258575A1 (en) Treatment of cancer and neurological diseases
AU2001284380A1 (en) Therapeutic and cosmetic uses of heparanases
AU7832700A (en) Ovarian tumor antigen and methods of use therefor
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AUPQ884500A0 (en) Novel therapeutic molecules and uses therefor - III
AU2001297571A1 (en) Detection and treatment of prostate cancer
AU3863900A (en) Prolyl peptidases and methods of use
SG90719A1 (en) Novel therapeutic and prophylactic agents and methods of using same
AU2001253560A1 (en) Methods of treatment
HUP0302882A3 (en) Improved specificity in treatment of diseases
AU2002366364A1 (en) E2f and cancer therapy